Loading...
Market
Story
Merck's CAPVAXIVE™ ($MRK) Vaccine Shows Positive Results in At-Risk Adults
Oct 16, 2024, 10:51 AM
Merck's CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) has demonstrated positive immune responses in adults with an increased risk for pneumococcal disease. The new Phase 3 data was shared at IDWeek 2024, highlighting the vaccine's efficacy in providing immune protection against pneumococcal disease, a significant concern for at-risk populations. The vaccine's development is a notable achievement for Merck ($MRK).
View original story
Similar markets
Yes • 50%
No • 50%
Capvaxive leads • 33%
Prevnar 20 leads • 33%
Equal market share • 33%
<10% • 25%
10-20% • 25%
20-30% • 25%
>30% • 25%
Capvaxive preferred • 33%
Prevnar 20 preferred • 33%
No preference • 33%
Approved in all major markets • 25%
Approved in some major markets • 25%
Not approved in any major markets • 25%
Approval status pending • 25%
Pfizer • 25%
Merck • 25%
Both equally • 25%
Neither • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Yes • 50%
No • 50%
Pfizer • 25%
GlaxoSmithKline • 25%
Moderna • 25%
Other • 25%
Less than 25% • 25%
25-50% • 25%
50-75% • 25%
More than 75% • 25%